Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1406&sort=other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1407&sort=other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=other_investigators" }, "data": [ { "type": "Grant", "id": "7337", "attributes": { "award_id": "3UH3OD023285-05S2", "title": "Prenatal Exposures and Child Health Outcomes: A Statewide Study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 10604, "first_name": "SUSAN ALISON", "last_name": "Laessig", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2016-09-21", "end_date": "2021-08-31", "award_amount": 305679, "principal_investigator": { "id": 23123, "first_name": "Charles James", "last_name": "Barone", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 521, "ror": "https://ror.org/05hs6h993", "name": "Michigan State University", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23124, "first_name": "MICHAEL R.", "last_name": "ELLIOTT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23125, "first_name": "Jean Marie", "last_name": "Kerver", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23126, "first_name": "Patricia", "last_name": "McKane", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23127, "first_name": "NIGEL SEFTON", "last_name": "PANETH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23128, "first_name": "Douglas M", "last_name": "Ruden", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 521, "ror": "https://ror.org/05hs6h993", "name": "Michigan State University", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Evidence from epidemiologic studies demonstrates the negative effects of both chronic and acute stress during gestation. These effects may occur perinatally or later in the child's life. The COVID-19 global pandemic has led to unprecedented mass disruption of social and financial security as well as changes in medical care delivery. These conditions are causing elevated levels of distress even for portions of the population that may have previously been protected from psychosocial stress. Of particular concern for pregnant women and their children, there may be direct biological effects related to infection with SARS-CoV-2 as well as substantial indirect psychosocial effects during critical periods of development with long-lasting impact on children relevant to the Environmental Child Health Outcomes (ECHO) program. This proposal addresses how psychosocial stress related to the COVID pandemic may impact perinatal and neurodevelopmental outcomes. Furthermore, evidence suggests that psychosocial stress is associated with both the gastrointestinal and vaginal microbiomes. Therefore, we will determine if maternal microbiomes or infant microbiomes mediate the impact of psychosocial stress on perinatal and neurodevelopmental outcomes. In aim 1, we address the maternal microbes and their role in mediating perinatal outcomes caused by maternal psychosocial stress during pregnancy. In aim 2, we focus on maternal psychosocial stress and its impact on neurodevelopment as mediated by the changes to the infant microbiota. We will examine these objectives in the context of our ongoing work, and as an extension of the parent grant (UG3/UH3OD023285, Paneth), where our organizing principle is that for many environmental exposures the most sensitive period of risk for child health is pregnancy and the perinatal period. The parent grant explores three primary exposures: toxic, nutritional, and inflammatory in a stratified random sample of state births recruited in the first trimester of pregnancy. Of the planned 1,100 new enrollments of cohort dyads into ECHO, more than 700 pregnant women have been consented, and, with a 75% follow up rate, more than 400 children have already been seen in infancy. Over 300 women are expected to be enrolled during the project period. While this research will leverage the local ECHO cohort, the project is designed to engage ECHO team science through two distinct but complementary ECHO-wide projects: (1) incorporation of data from two cohorts (O'Conner & Deoni) to address the aims proposed above and (2) provision of data and biospecimens to separate COVID supplement (Transande) which addresses SARS-CoV-2 seropositivity/COVID illness as well as psychosocial stress (assessed via questionnaire and cortisol measured in hair) as they relate to shortened gestation and other perinatal outcomes. Our efforts will not only inform the specific hypotheses being tested but will also inform “touch-free” methods for sample collection and patient interaction. The work proposed herein complements the parent grant by addressing an exposure (maternal psychosocial stress during a time of pandemic), not included in the parent grant, and at least two of ECHO's outcomes (PPP and neurodevelopment).", "keywords": [ "2019-nCoV", "Address", "Age", "Age-Months", "Archives", "Biological", "Birth", "COVID-19", "COVID-19 pandemic", "Child", "Child Health", "Chronic stress", "Clinical Research", "Collaborations", "Collection", "Complement", "Consent", "Data", "Development", "Distress", "Enrollment", "Environment", "Environmental Exposure", "First Pregnancy Trimester", "Generations", "Hair", "Health", "Hydrocortisone", "Infant", "Infection", "Inflammatory", "Intervention", "Length", "Life", "Link", "Maternal and Child Health", "Measures", "Mediating", "Medical", "Methods", "Michigan", "Microbe", "Mission", "Neurocognitive", "Nutritional", "Outcome", "Patients", "Perinatal", "Population", "Pregnancy", "Pregnant Women", "Procedures", "Psychosocial Stress", "Public Health", "Questionnaires", "Research", "Risk", "Role", "Sampling", "Science", "Security", "Shotguns", "Symptoms", "Testing", "Third Pregnancy Trimester", "Time", "Touch sensation", "Toxicant exposure", "Treatment/Psychosocial Effects", "Vertical Disease Transmission", "Woman", "Work", "acute stress", "care delivery", "cohort", "coronavirus disease", "critical period", "design", "epidemiology study", "experience", "fecal microbiome", "fecal microbiota", "follow-up", "gut microbiome", "gut microbiota", "infancy", "maternal microbiome", "maternal stress", "metagenomic sequencing", "microbial", "microbiome", "microbiome alteration", "microbiota", "neurodevelopment", "neurodevelopmental effect", "novel", "offspring", "pandemic disease", "parent grant", "perinatal outcomes", "perinatal period", "preclinical study", "prenatal exposure", "programs", "recruit", "sample collection", "seropositive", "social", "vaginal microbiome", "vaginal microbiota" ], "approved": true } }, { "type": "Grant", "id": "7337", "attributes": { "award_id": "3UH3OD023285-05S2", "title": "Prenatal Exposures and Child Health Outcomes: A Statewide Study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 10604, "first_name": "SUSAN ALISON", "last_name": "Laessig", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2016-09-21", "end_date": "2021-08-31", "award_amount": 305679, "principal_investigator": { "id": 23123, "first_name": "Charles James", "last_name": "Barone", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 521, "ror": "https://ror.org/05hs6h993", "name": "Michigan State University", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23124, "first_name": "MICHAEL R.", "last_name": "ELLIOTT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23125, "first_name": "Jean Marie", "last_name": "Kerver", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23126, "first_name": "Patricia", "last_name": "McKane", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23127, "first_name": "NIGEL SEFTON", "last_name": "PANETH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23128, "first_name": "Douglas M", "last_name": "Ruden", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 521, "ror": "https://ror.org/05hs6h993", "name": "Michigan State University", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Evidence from epidemiologic studies demonstrates the negative effects of both chronic and acute stress during gestation. These effects may occur perinatally or later in the child's life. The COVID-19 global pandemic has led to unprecedented mass disruption of social and financial security as well as changes in medical care delivery. These conditions are causing elevated levels of distress even for portions of the population that may have previously been protected from psychosocial stress. Of particular concern for pregnant women and their children, there may be direct biological effects related to infection with SARS-CoV-2 as well as substantial indirect psychosocial effects during critical periods of development with long-lasting impact on children relevant to the Environmental Child Health Outcomes (ECHO) program. This proposal addresses how psychosocial stress related to the COVID pandemic may impact perinatal and neurodevelopmental outcomes. Furthermore, evidence suggests that psychosocial stress is associated with both the gastrointestinal and vaginal microbiomes. Therefore, we will determine if maternal microbiomes or infant microbiomes mediate the impact of psychosocial stress on perinatal and neurodevelopmental outcomes. In aim 1, we address the maternal microbes and their role in mediating perinatal outcomes caused by maternal psychosocial stress during pregnancy. In aim 2, we focus on maternal psychosocial stress and its impact on neurodevelopment as mediated by the changes to the infant microbiota. We will examine these objectives in the context of our ongoing work, and as an extension of the parent grant (UG3/UH3OD023285, Paneth), where our organizing principle is that for many environmental exposures the most sensitive period of risk for child health is pregnancy and the perinatal period. The parent grant explores three primary exposures: toxic, nutritional, and inflammatory in a stratified random sample of state births recruited in the first trimester of pregnancy. Of the planned 1,100 new enrollments of cohort dyads into ECHO, more than 700 pregnant women have been consented, and, with a 75% follow up rate, more than 400 children have already been seen in infancy. Over 300 women are expected to be enrolled during the project period. While this research will leverage the local ECHO cohort, the project is designed to engage ECHO team science through two distinct but complementary ECHO-wide projects: (1) incorporation of data from two cohorts (O'Conner & Deoni) to address the aims proposed above and (2) provision of data and biospecimens to separate COVID supplement (Transande) which addresses SARS-CoV-2 seropositivity/COVID illness as well as psychosocial stress (assessed via questionnaire and cortisol measured in hair) as they relate to shortened gestation and other perinatal outcomes. Our efforts will not only inform the specific hypotheses being tested but will also inform “touch-free” methods for sample collection and patient interaction. The work proposed herein complements the parent grant by addressing an exposure (maternal psychosocial stress during a time of pandemic), not included in the parent grant, and at least two of ECHO's outcomes (PPP and neurodevelopment).", "keywords": [ "2019-nCoV", "Address", "Age", "Age-Months", "Archives", "Biological", "Birth", "COVID-19", "COVID-19 pandemic", "Child", "Child Health", "Chronic stress", "Clinical Research", "Collaborations", "Collection", "Complement", "Consent", "Data", "Development", "Distress", "Enrollment", "Environment", "Environmental Exposure", "First Pregnancy Trimester", "Generations", "Hair", "Health", "Hydrocortisone", "Infant", "Infection", "Inflammatory", "Intervention", "Length", "Life", "Link", "Maternal and Child Health", "Measures", "Mediating", "Medical", "Methods", "Michigan", "Microbe", "Mission", "Neurocognitive", "Nutritional", "Outcome", "Patients", "Perinatal", "Population", "Pregnancy", "Pregnant Women", "Procedures", "Psychosocial Stress", "Public Health", "Questionnaires", "Research", "Risk", "Role", "Sampling", "Science", "Security", "Shotguns", "Symptoms", "Testing", "Third Pregnancy Trimester", "Time", "Touch sensation", "Toxicant exposure", "Treatment/Psychosocial Effects", "Vertical Disease Transmission", "Woman", "Work", "acute stress", "care delivery", "cohort", "coronavirus disease", "critical period", "design", "epidemiology study", "experience", "fecal microbiome", "fecal microbiota", "follow-up", "gut microbiome", "gut microbiota", "infancy", "maternal microbiome", "maternal stress", "metagenomic sequencing", "microbial", "microbiome", "microbiome alteration", "microbiota", "neurodevelopment", "neurodevelopmental effect", "novel", "offspring", "pandemic disease", "parent grant", "perinatal outcomes", "perinatal period", "preclinical study", "prenatal exposure", "programs", "recruit", "sample collection", "seropositive", "social", "vaginal microbiome", "vaginal microbiota" ], "approved": true } }, { "type": "Grant", "id": "7337", "attributes": { "award_id": "3UH3OD023285-05S2", "title": "Prenatal Exposures and Child Health Outcomes: A Statewide Study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 10604, "first_name": "SUSAN ALISON", "last_name": "Laessig", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2016-09-21", "end_date": "2021-08-31", "award_amount": 305679, "principal_investigator": { "id": 23123, "first_name": "Charles James", "last_name": "Barone", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 521, "ror": "https://ror.org/05hs6h993", "name": "Michigan State University", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23124, "first_name": "MICHAEL R.", "last_name": "ELLIOTT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23125, "first_name": "Jean Marie", "last_name": "Kerver", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23126, "first_name": "Patricia", "last_name": "McKane", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23127, "first_name": "NIGEL SEFTON", "last_name": "PANETH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23128, "first_name": "Douglas M", "last_name": "Ruden", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 521, "ror": "https://ror.org/05hs6h993", "name": "Michigan State University", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Evidence from epidemiologic studies demonstrates the negative effects of both chronic and acute stress during gestation. These effects may occur perinatally or later in the child's life. The COVID-19 global pandemic has led to unprecedented mass disruption of social and financial security as well as changes in medical care delivery. These conditions are causing elevated levels of distress even for portions of the population that may have previously been protected from psychosocial stress. Of particular concern for pregnant women and their children, there may be direct biological effects related to infection with SARS-CoV-2 as well as substantial indirect psychosocial effects during critical periods of development with long-lasting impact on children relevant to the Environmental Child Health Outcomes (ECHO) program. This proposal addresses how psychosocial stress related to the COVID pandemic may impact perinatal and neurodevelopmental outcomes. Furthermore, evidence suggests that psychosocial stress is associated with both the gastrointestinal and vaginal microbiomes. Therefore, we will determine if maternal microbiomes or infant microbiomes mediate the impact of psychosocial stress on perinatal and neurodevelopmental outcomes. In aim 1, we address the maternal microbes and their role in mediating perinatal outcomes caused by maternal psychosocial stress during pregnancy. In aim 2, we focus on maternal psychosocial stress and its impact on neurodevelopment as mediated by the changes to the infant microbiota. We will examine these objectives in the context of our ongoing work, and as an extension of the parent grant (UG3/UH3OD023285, Paneth), where our organizing principle is that for many environmental exposures the most sensitive period of risk for child health is pregnancy and the perinatal period. The parent grant explores three primary exposures: toxic, nutritional, and inflammatory in a stratified random sample of state births recruited in the first trimester of pregnancy. Of the planned 1,100 new enrollments of cohort dyads into ECHO, more than 700 pregnant women have been consented, and, with a 75% follow up rate, more than 400 children have already been seen in infancy. Over 300 women are expected to be enrolled during the project period. While this research will leverage the local ECHO cohort, the project is designed to engage ECHO team science through two distinct but complementary ECHO-wide projects: (1) incorporation of data from two cohorts (O'Conner & Deoni) to address the aims proposed above and (2) provision of data and biospecimens to separate COVID supplement (Transande) which addresses SARS-CoV-2 seropositivity/COVID illness as well as psychosocial stress (assessed via questionnaire and cortisol measured in hair) as they relate to shortened gestation and other perinatal outcomes. Our efforts will not only inform the specific hypotheses being tested but will also inform “touch-free” methods for sample collection and patient interaction. The work proposed herein complements the parent grant by addressing an exposure (maternal psychosocial stress during a time of pandemic), not included in the parent grant, and at least two of ECHO's outcomes (PPP and neurodevelopment).", "keywords": [ "2019-nCoV", "Address", "Age", "Age-Months", "Archives", "Biological", "Birth", "COVID-19", "COVID-19 pandemic", "Child", "Child Health", "Chronic stress", "Clinical Research", "Collaborations", "Collection", "Complement", "Consent", "Data", "Development", "Distress", "Enrollment", "Environment", "Environmental Exposure", "First Pregnancy Trimester", "Generations", "Hair", "Health", "Hydrocortisone", "Infant", "Infection", "Inflammatory", "Intervention", "Length", "Life", "Link", "Maternal and Child Health", "Measures", "Mediating", "Medical", "Methods", "Michigan", "Microbe", "Mission", "Neurocognitive", "Nutritional", "Outcome", "Patients", "Perinatal", "Population", "Pregnancy", "Pregnant Women", "Procedures", "Psychosocial Stress", "Public Health", "Questionnaires", "Research", "Risk", "Role", "Sampling", "Science", "Security", "Shotguns", "Symptoms", "Testing", "Third Pregnancy Trimester", "Time", "Touch sensation", "Toxicant exposure", "Treatment/Psychosocial Effects", "Vertical Disease Transmission", "Woman", "Work", "acute stress", "care delivery", "cohort", "coronavirus disease", "critical period", "design", "epidemiology study", "experience", "fecal microbiome", "fecal microbiota", "follow-up", "gut microbiome", "gut microbiota", "infancy", "maternal microbiome", "maternal stress", "metagenomic sequencing", "microbial", "microbiome", "microbiome alteration", "microbiota", "neurodevelopment", "neurodevelopmental effect", "novel", "offspring", "pandemic disease", "parent grant", "perinatal outcomes", "perinatal period", "preclinical study", "prenatal exposure", "programs", "recruit", "sample collection", "seropositive", "social", "vaginal microbiome", "vaginal microbiota" ], "approved": true } }, { "type": "Grant", "id": "7339", "attributes": { "award_id": "3R34DA050290-01S2", "title": "4/7: Longitudinal Evaluation of the Impact of the COVID-19 Pandemic on High-risk New and Expectant Mothers", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 10219, "first_name": "Vani", "last_name": "Pariyadath", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2019-09-30", "end_date": "2021-03-31", "award_amount": 158349, "principal_investigator": { "id": 22880, "first_name": "Elizabeth E", "last_name": "Krans", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23130, "first_name": "BEATRIZ", "last_name": "LUNA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, { "id": 23131, "first_name": "Ashok", "last_name": "Panigrahy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "While the rate of neonatal abstinence syndrome has reached a staggering 6.5 per 1,000 births nationwide, the short- and long-term effects of in-utero opioid exposure are far from clear. We lack fundamental knowledge of neurotypical neonatal development and struggle to disentangle the effect of opioid exposure from other protective and risk factors impacting infant health. The fetal stage of brain development is a critical period when foundational aspects of brain structure and function are being established. In addition, postnatal brain development and specialization are shaped by environmental experiences thus allowing maturation to be influenced by lifestyle factors associated with opioid use. This Phase I project will plan for a large scale, multi- site research study to prospectively examine human brain, cognitive, behavioral, social, and emotional development beginning prenatally through childhood. The University of Pittsburgh is one of four linked sites including Oregon Health and Sciences University, New York University and the University of Vermont that will address key challenges critical to the success of the planned Phase II study. Aim 1 will develop, implement and evaluate innovative recruitment and retention strategies for high-risk populations through a longitudinal survey of 150 pregnant women per site (n=600 across sites), half of whom are opioid using. Aim 2 will implement a multi-site, standardized, longitudinal research protocol by enrolling 20 pregnant women per site (n=80 across sites), half of whom are opioid using. This prospective longitudinal study will collect fetal and neonatal multimodal MRI, biospecimens, and maternal psychosocial and health assessments. Aim 3 will evaluate data acquisition, processing, and statistical considerations to maximize data quality, usability, and integration across sites. We will test the efficacy of (A) real-time motion monitoring/quality assessment for improving overall data quality and (B) time-savings versus MRI quality using new acceleration sequence protocols. This approach will inform and set a strong foundation for a comprehensive and effective Phase II research plan. The University of Pittsburgh site is led by a highly productive, NIH-funded investigative team with multidisciplinary expertise in substance use (Krans, Bogen), pregnancy (Krans), and fetal, neonatal, and pediatric neuroimaging (Luna, Panigrahy). Specifically, our team has established study protocols that yield excellent recruitment (~76%) and retention (~74%) rates among opioid using pregnant women, has substantial experience with imaging the immature brain (fetal/neonatal) and is a leader in developmental cognitive neuroscience using multimodal imaging to investigate neural mechanisms underlying neurocognitive development through adolescence. We will leverage our on-going, NIH-funded, multi-center neuroimaging studies to provide imaging harmonization techniques and assist with the development of structural fetal brain and placental imaging pipeline for all linked sites to assistant with development of Phase II protocol. Further, we will pilot innovative studies of age-related Iron deposition and quantitative fetal MR spectroscopy.", "keywords": [ "Acceleration", "Address", "Adolescence", "Alcohol or Other Drugs use", "Apgar Score", "Behavioral", "Biological", "Biological Specimen Banks", "Biology", "Birth", "Birth Records", "Brain", "COVID-19", "COVID-19 pandemic", "Caring", "Child", "Child Health", "Child Rearing", "Childhood", "Cognitive", "Collection", "Communities", "Coping Behavior", "Data", "Data Set", "Deposition", "Development", "Developmental Delay Disorders", "Economics", "Emotional", "Enrollment", "Equation", "Event", "Exposure to", "Factor Analysis", "Fetal Structures", "Foundations", "Funding", "Future", "Gene Expression", "Geographic Locations", "Geography", "Gestational Age", "Health", "Health Sciences", "Healthcare", "Human", "Human Development", "Image", "Impact evaluation", "Individual", "Infant", "Infant Health", "Institution", "Intervention", "Iron", "Knowledge", "Life", "Link", "Local Government", "Long-Term Effects", "Longitudinal Surveys", "Longitudinal prospective study", "Low Birth Weight Infant", "Magnetic Resonance Imaging", "Magnetic Resonance Spectroscopy", "Medical Economics", "Medical center", "Mental Health", "Modeling", "Monitor", "Mothers", "Motion", "Multimodal Imaging", "Neonatal", "Neonatal Abstinence Syndrome", "Neurocognitive", "New York", "Oregon", "Outcome", "Parents", "Perinatal", "Phase", "Phase II Clinical Trials", "Policies", "Postpartum Period", "Postpartum Women", "Predisposition", "Pregnancy", "Pregnant Women", "Protocols documentation", "Proxy", "Psychological Stress", "Psychosocial Assessment and Care", "Recording of previous events", "Research", "Resources", "Risk", "Risk Factors", "Sampling", "Savings", "Severities", "Site", "Social support", "Specimen", "Standardization", "Stress", "Structure", "Surveys", "Techniques", "Testing", "Time", "Uncertainty", "United States National Institutes of Health", "Universities", "Variant", "Vermont", "Viral", "Virus", "Vulnerable Populations", "Washington", "Woman", "Work", "age related", "behavioral health", "brain health", "cognitive development", "cognitive neuroscience", "cohort", "contextual factors", "coping", "coronavirus disease", "critical period", "data acquisition", "data quality", "efficacy testing", "experience", "fetal", "health assessment", "health economics", "high risk", "high risk population", "improved", "in utero", "indexing", "individual variation", "infant temperament", "inflammatory marker", "innovation", "interest", "lifestyle factors", "mat" ], "approved": true } }, { "type": "Grant", "id": "7339", "attributes": { "award_id": "3R34DA050290-01S2", "title": "4/7: Longitudinal Evaluation of the Impact of the COVID-19 Pandemic on High-risk New and Expectant Mothers", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 10219, "first_name": "Vani", "last_name": "Pariyadath", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2019-09-30", "end_date": "2021-03-31", "award_amount": 158349, "principal_investigator": { "id": 22880, "first_name": "Elizabeth E", "last_name": "Krans", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23130, "first_name": "BEATRIZ", "last_name": "LUNA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, { "id": 23131, "first_name": "Ashok", "last_name": "Panigrahy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "While the rate of neonatal abstinence syndrome has reached a staggering 6.5 per 1,000 births nationwide, the short- and long-term effects of in-utero opioid exposure are far from clear. We lack fundamental knowledge of neurotypical neonatal development and struggle to disentangle the effect of opioid exposure from other protective and risk factors impacting infant health. The fetal stage of brain development is a critical period when foundational aspects of brain structure and function are being established. In addition, postnatal brain development and specialization are shaped by environmental experiences thus allowing maturation to be influenced by lifestyle factors associated with opioid use. This Phase I project will plan for a large scale, multi- site research study to prospectively examine human brain, cognitive, behavioral, social, and emotional development beginning prenatally through childhood. The University of Pittsburgh is one of four linked sites including Oregon Health and Sciences University, New York University and the University of Vermont that will address key challenges critical to the success of the planned Phase II study. Aim 1 will develop, implement and evaluate innovative recruitment and retention strategies for high-risk populations through a longitudinal survey of 150 pregnant women per site (n=600 across sites), half of whom are opioid using. Aim 2 will implement a multi-site, standardized, longitudinal research protocol by enrolling 20 pregnant women per site (n=80 across sites), half of whom are opioid using. This prospective longitudinal study will collect fetal and neonatal multimodal MRI, biospecimens, and maternal psychosocial and health assessments. Aim 3 will evaluate data acquisition, processing, and statistical considerations to maximize data quality, usability, and integration across sites. We will test the efficacy of (A) real-time motion monitoring/quality assessment for improving overall data quality and (B) time-savings versus MRI quality using new acceleration sequence protocols. This approach will inform and set a strong foundation for a comprehensive and effective Phase II research plan. The University of Pittsburgh site is led by a highly productive, NIH-funded investigative team with multidisciplinary expertise in substance use (Krans, Bogen), pregnancy (Krans), and fetal, neonatal, and pediatric neuroimaging (Luna, Panigrahy). Specifically, our team has established study protocols that yield excellent recruitment (~76%) and retention (~74%) rates among opioid using pregnant women, has substantial experience with imaging the immature brain (fetal/neonatal) and is a leader in developmental cognitive neuroscience using multimodal imaging to investigate neural mechanisms underlying neurocognitive development through adolescence. We will leverage our on-going, NIH-funded, multi-center neuroimaging studies to provide imaging harmonization techniques and assist with the development of structural fetal brain and placental imaging pipeline for all linked sites to assistant with development of Phase II protocol. Further, we will pilot innovative studies of age-related Iron deposition and quantitative fetal MR spectroscopy.", "keywords": [ "Acceleration", "Address", "Adolescence", "Alcohol or Other Drugs use", "Apgar Score", "Behavioral", "Biological", "Biological Specimen Banks", "Biology", "Birth", "Birth Records", "Brain", "COVID-19", "COVID-19 pandemic", "Caring", "Child", "Child Health", "Child Rearing", "Childhood", "Cognitive", "Collection", "Communities", "Coping Behavior", "Data", "Data Set", "Deposition", "Development", "Developmental Delay Disorders", "Economics", "Emotional", "Enrollment", "Equation", "Event", "Exposure to", "Factor Analysis", "Fetal Structures", "Foundations", "Funding", "Future", "Gene Expression", "Geographic Locations", "Geography", "Gestational Age", "Health", "Health Sciences", "Healthcare", "Human", "Human Development", "Image", "Impact evaluation", "Individual", "Infant", "Infant Health", "Institution", "Intervention", "Iron", "Knowledge", "Life", "Link", "Local Government", "Long-Term Effects", "Longitudinal Surveys", "Longitudinal prospective study", "Low Birth Weight Infant", "Magnetic Resonance Imaging", "Magnetic Resonance Spectroscopy", "Medical Economics", "Medical center", "Mental Health", "Modeling", "Monitor", "Mothers", "Motion", "Multimodal Imaging", "Neonatal", "Neonatal Abstinence Syndrome", "Neurocognitive", "New York", "Oregon", "Outcome", "Parents", "Perinatal", "Phase", "Phase II Clinical Trials", "Policies", "Postpartum Period", "Postpartum Women", "Predisposition", "Pregnancy", "Pregnant Women", "Protocols documentation", "Proxy", "Psychological Stress", "Psychosocial Assessment and Care", "Recording of previous events", "Research", "Resources", "Risk", "Risk Factors", "Sampling", "Savings", "Severities", "Site", "Social support", "Specimen", "Standardization", "Stress", "Structure", "Surveys", "Techniques", "Testing", "Time", "Uncertainty", "United States National Institutes of Health", "Universities", "Variant", "Vermont", "Viral", "Virus", "Vulnerable Populations", "Washington", "Woman", "Work", "age related", "behavioral health", "brain health", "cognitive development", "cognitive neuroscience", "cohort", "contextual factors", "coping", "coronavirus disease", "critical period", "data acquisition", "data quality", "efficacy testing", "experience", "fetal", "health assessment", "health economics", "high risk", "high risk population", "improved", "in utero", "indexing", "individual variation", "infant temperament", "inflammatory marker", "innovation", "interest", "lifestyle factors", "mat" ], "approved": true } }, { "type": "Grant", "id": "7342", "attributes": { "award_id": "3U41HG007823-07S1", "title": "Establishing the GWAS Catalog as a resource for large-scale association studies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Human Genome Research Institute (NHGRI)" ], "program_reference_codes": [], "program_officials": [ { "id": 21484, "first_name": "KENNETH L", "last_name": "WILEY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2014-09-01", "end_date": "2022-06-30", "award_amount": 168829, "principal_investigator": { "id": 23134, "first_name": "Fiona", "last_name": "Cunningham", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1570, "ror": "https://ror.org/03mstc592", "name": "European Molecular Biology Laboratory", "address": "", "city": "", "state": "", "zip": "", "country": "GERMANY", "approved": true } ] }, "other_investigators": [ { "id": 23134, "first_name": "Fiona", "last_name": "Cunningham", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1570, "ror": "https://ror.org/03mstc592", "name": "European Molecular Biology Laboratory", "address": "", "city": "", "state": "", "zip": "", "country": "GERMANY", "approved": true } ] }, { "id": 23135, "first_name": "Paul", "last_name": "Flicek", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23136, "first_name": "Helen Elizabeth", "last_name": "Parkinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1570, "ror": "https://ror.org/03mstc592", "name": "European Molecular Biology Laboratory", "address": "", "city": "", "state": "", "zip": "", "country": "GERMANY", "approved": true }, "abstract": "PROJECT SUMMARY: Accelerating access and sharing of COVID-19 human host genetic and phenotype data Early evidence from twin studies suggests that approximately 50% of COVID-19 disease burden is determined by host genetics. The identification of host factors for COVID-19 will directly influence the development of public health intervention strategies and the identification of drug targets. There are a variety of existing cohort longitudinal studies with existing genetic and clinical data, e.g. UK Biobank, AllofUs, 23andMe, Ancestry.com who are engaging existing cohort participants for information on COVID-19 disease burden. The COVID-19 Host Genetics Initiative (COVID-19-HGI) is an international consortium that aims to identify host genetic associations of COVID-19 by combining data from human cohorts. The European Genome-phenome Archive (EGA) and the NHGRI Analysis, Visualization, and Informatics Lab-space AnVIL/Terra platforms are founding partners that form the data sharing and analysis platform. The EGA is a GA4GH driver project and can rapidly acquire these data enabling ethical genomic data sharing. This extends the international data sharing infrastructure and processes enabling access to human controlled access data relevant to addressing the COVID-19 pandemic. Aim 1: Host submissions to the COVID-19-HGI data sharing platform The EGA has previously received submissions from over 144 US submitters and US based users represent 33% of the total user community which streams 8.6 PB of data last year. The COVID-19 pandemic is expected to significantly increase this number through planned new industrial collaboration (e.g. Ancestry.com, Regeneron Pharmaceuticals). There is an opportunity to develop new submission templates and processes to enable more rapid submission of genetic and phenotype data. Aim 2: COVID-19 host metadata harmonisation Recording and collection of clinical patient data of COVID-19 disease burden is a critical requirement. Phenotype information is collected using a variety of formats, coding schemes, surveys, and ontologies. Using the COVID-19-HGI data dictionary, we will construct a common minimal metadata model that will map across COVID-19 studies for genetic association studies. Aim 3: Rapid integrated data access and flow into COVID-19-HGI analysis platform Rapid integration of new human genotypes and phenotyping will be essential to determine reliable and well supported genetic associations. The NHGRI AnVIL and Terra platform will be the analysis platform for the COVID-19-HGI. We will use GA4GH standards to provide rapid data access and integration of US COVID- 19 data. This will result in more rapid and seamless human data flow between EGA and AnVIL to provide additional power to COVID-19 host association studies", "keywords": [ "Address", "Age", "Archives", "Authorization documentation", "COVID-19", "COVID-19 pandemic", "Catalogs", "Cessation of life", "Clinical", "Clinical Data", "Code", "Cohort Studies", "Collaborations", "Collection", "Communities", "Coupled", "Data", "Data Analyses", "Data Science", "Data Set", "Development", "Disease", "Drug Targeting", "Ensure", "Environment", "Ethics", "European", "Fast Healthcare Interoperability Resources", "Finland", "Gender", "Genetic", "Genetic study", "Genome", "Genotype", "Health", "Healthcare", "Hospitalization", "Hospitals", "Human", "Individual", "Industrialization", "Infection", "Informatics", "Infrastructure", "Integration Host Factors", "International", "Intervention", "Investments", "Length of Stay", "Life Style", "Longitudinal cohort study", "Maps", "Measures", "Mediating", "Metadata", "Methods", "Modeling", "National Human Genome Research Institute", "Ontology", "Parkinson Disease", "Participant", "Patients", "Pharmacologic Substance", "Phenotype", "Policies", "Process", "Research", "Research Personnel", "Resources", "Risk Factors", "Role", "Scheme", "Secure", "Semantics", "Severity of illness", "Source", "Spain", "Standardization", "Stream", "Surveys", "Sweden", "Symptoms", "System", "Time", "Twin Studies", "Visualization", "base", "biobank", "burden of illness", "cohort", "comorbidity", "coronavirus disease", "data access", "data dictionary", "data integration", "data sharing", "demographics", "design", "disease heterogeneity", "distributed data", "genetic association", "genome wide association study", "genomic data", "human data", "improved", "novel", "personalized medicine", "phenome", "phenotypic data", "public health intervention", "sharing platform" ], "approved": true } }, { "type": "Grant", "id": "7342", "attributes": { "award_id": "3U41HG007823-07S1", "title": "Establishing the GWAS Catalog as a resource for large-scale association studies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Human Genome Research Institute (NHGRI)" ], "program_reference_codes": [], "program_officials": [ { "id": 21484, "first_name": "KENNETH L", "last_name": "WILEY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2014-09-01", "end_date": "2022-06-30", "award_amount": 168829, "principal_investigator": { "id": 23134, "first_name": "Fiona", "last_name": "Cunningham", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1570, "ror": "https://ror.org/03mstc592", "name": "European Molecular Biology Laboratory", "address": "", "city": "", "state": "", "zip": "", "country": "GERMANY", "approved": true } ] }, "other_investigators": [ { "id": 23134, "first_name": "Fiona", "last_name": "Cunningham", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1570, "ror": "https://ror.org/03mstc592", "name": "European Molecular Biology Laboratory", "address": "", "city": "", "state": "", "zip": "", "country": "GERMANY", "approved": true } ] }, { "id": 23135, "first_name": "Paul", "last_name": "Flicek", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23136, "first_name": "Helen Elizabeth", "last_name": "Parkinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1570, "ror": "https://ror.org/03mstc592", "name": "European Molecular Biology Laboratory", "address": "", "city": "", "state": "", "zip": "", "country": "GERMANY", "approved": true }, "abstract": "PROJECT SUMMARY: Accelerating access and sharing of COVID-19 human host genetic and phenotype data Early evidence from twin studies suggests that approximately 50% of COVID-19 disease burden is determined by host genetics. The identification of host factors for COVID-19 will directly influence the development of public health intervention strategies and the identification of drug targets. There are a variety of existing cohort longitudinal studies with existing genetic and clinical data, e.g. UK Biobank, AllofUs, 23andMe, Ancestry.com who are engaging existing cohort participants for information on COVID-19 disease burden. The COVID-19 Host Genetics Initiative (COVID-19-HGI) is an international consortium that aims to identify host genetic associations of COVID-19 by combining data from human cohorts. The European Genome-phenome Archive (EGA) and the NHGRI Analysis, Visualization, and Informatics Lab-space AnVIL/Terra platforms are founding partners that form the data sharing and analysis platform. The EGA is a GA4GH driver project and can rapidly acquire these data enabling ethical genomic data sharing. This extends the international data sharing infrastructure and processes enabling access to human controlled access data relevant to addressing the COVID-19 pandemic. Aim 1: Host submissions to the COVID-19-HGI data sharing platform The EGA has previously received submissions from over 144 US submitters and US based users represent 33% of the total user community which streams 8.6 PB of data last year. The COVID-19 pandemic is expected to significantly increase this number through planned new industrial collaboration (e.g. Ancestry.com, Regeneron Pharmaceuticals). There is an opportunity to develop new submission templates and processes to enable more rapid submission of genetic and phenotype data. Aim 2: COVID-19 host metadata harmonisation Recording and collection of clinical patient data of COVID-19 disease burden is a critical requirement. Phenotype information is collected using a variety of formats, coding schemes, surveys, and ontologies. Using the COVID-19-HGI data dictionary, we will construct a common minimal metadata model that will map across COVID-19 studies for genetic association studies. Aim 3: Rapid integrated data access and flow into COVID-19-HGI analysis platform Rapid integration of new human genotypes and phenotyping will be essential to determine reliable and well supported genetic associations. The NHGRI AnVIL and Terra platform will be the analysis platform for the COVID-19-HGI. We will use GA4GH standards to provide rapid data access and integration of US COVID- 19 data. This will result in more rapid and seamless human data flow between EGA and AnVIL to provide additional power to COVID-19 host association studies", "keywords": [ "Address", "Age", "Archives", "Authorization documentation", "COVID-19", "COVID-19 pandemic", "Catalogs", "Cessation of life", "Clinical", "Clinical Data", "Code", "Cohort Studies", "Collaborations", "Collection", "Communities", "Coupled", "Data", "Data Analyses", "Data Science", "Data Set", "Development", "Disease", "Drug Targeting", "Ensure", "Environment", "Ethics", "European", "Fast Healthcare Interoperability Resources", "Finland", "Gender", "Genetic", "Genetic study", "Genome", "Genotype", "Health", "Healthcare", "Hospitalization", "Hospitals", "Human", "Individual", "Industrialization", "Infection", "Informatics", "Infrastructure", "Integration Host Factors", "International", "Intervention", "Investments", "Length of Stay", "Life Style", "Longitudinal cohort study", "Maps", "Measures", "Mediating", "Metadata", "Methods", "Modeling", "National Human Genome Research Institute", "Ontology", "Parkinson Disease", "Participant", "Patients", "Pharmacologic Substance", "Phenotype", "Policies", "Process", "Research", "Research Personnel", "Resources", "Risk Factors", "Role", "Scheme", "Secure", "Semantics", "Severity of illness", "Source", "Spain", "Standardization", "Stream", "Surveys", "Sweden", "Symptoms", "System", "Time", "Twin Studies", "Visualization", "base", "biobank", "burden of illness", "cohort", "comorbidity", "coronavirus disease", "data access", "data dictionary", "data integration", "data sharing", "demographics", "design", "disease heterogeneity", "distributed data", "genetic association", "genome wide association study", "genomic data", "human data", "improved", "novel", "personalized medicine", "phenome", "phenotypic data", "public health intervention", "sharing platform" ], "approved": true } }, { "type": "Grant", "id": "7342", "attributes": { "award_id": "3U41HG007823-07S1", "title": "Establishing the GWAS Catalog as a resource for large-scale association studies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Human Genome Research Institute (NHGRI)" ], "program_reference_codes": [], "program_officials": [ { "id": 21484, "first_name": "KENNETH L", "last_name": "WILEY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2014-09-01", "end_date": "2022-06-30", "award_amount": 168829, "principal_investigator": { "id": 23134, "first_name": "Fiona", "last_name": "Cunningham", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1570, "ror": "https://ror.org/03mstc592", "name": "European Molecular Biology Laboratory", "address": "", "city": "", "state": "", "zip": "", "country": "GERMANY", "approved": true } ] }, "other_investigators": [ { "id": 23134, "first_name": "Fiona", "last_name": "Cunningham", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1570, "ror": "https://ror.org/03mstc592", "name": "European Molecular Biology Laboratory", "address": "", "city": "", "state": "", "zip": "", "country": "GERMANY", "approved": true } ] }, { "id": 23135, "first_name": "Paul", "last_name": "Flicek", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23136, "first_name": "Helen Elizabeth", "last_name": "Parkinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1570, "ror": "https://ror.org/03mstc592", "name": "European Molecular Biology Laboratory", "address": "", "city": "", "state": "", "zip": "", "country": "GERMANY", "approved": true }, "abstract": "PROJECT SUMMARY: Accelerating access and sharing of COVID-19 human host genetic and phenotype data Early evidence from twin studies suggests that approximately 50% of COVID-19 disease burden is determined by host genetics. The identification of host factors for COVID-19 will directly influence the development of public health intervention strategies and the identification of drug targets. There are a variety of existing cohort longitudinal studies with existing genetic and clinical data, e.g. UK Biobank, AllofUs, 23andMe, Ancestry.com who are engaging existing cohort participants for information on COVID-19 disease burden. The COVID-19 Host Genetics Initiative (COVID-19-HGI) is an international consortium that aims to identify host genetic associations of COVID-19 by combining data from human cohorts. The European Genome-phenome Archive (EGA) and the NHGRI Analysis, Visualization, and Informatics Lab-space AnVIL/Terra platforms are founding partners that form the data sharing and analysis platform. The EGA is a GA4GH driver project and can rapidly acquire these data enabling ethical genomic data sharing. This extends the international data sharing infrastructure and processes enabling access to human controlled access data relevant to addressing the COVID-19 pandemic. Aim 1: Host submissions to the COVID-19-HGI data sharing platform The EGA has previously received submissions from over 144 US submitters and US based users represent 33% of the total user community which streams 8.6 PB of data last year. The COVID-19 pandemic is expected to significantly increase this number through planned new industrial collaboration (e.g. Ancestry.com, Regeneron Pharmaceuticals). There is an opportunity to develop new submission templates and processes to enable more rapid submission of genetic and phenotype data. Aim 2: COVID-19 host metadata harmonisation Recording and collection of clinical patient data of COVID-19 disease burden is a critical requirement. Phenotype information is collected using a variety of formats, coding schemes, surveys, and ontologies. Using the COVID-19-HGI data dictionary, we will construct a common minimal metadata model that will map across COVID-19 studies for genetic association studies. Aim 3: Rapid integrated data access and flow into COVID-19-HGI analysis platform Rapid integration of new human genotypes and phenotyping will be essential to determine reliable and well supported genetic associations. The NHGRI AnVIL and Terra platform will be the analysis platform for the COVID-19-HGI. We will use GA4GH standards to provide rapid data access and integration of US COVID- 19 data. This will result in more rapid and seamless human data flow between EGA and AnVIL to provide additional power to COVID-19 host association studies", "keywords": [ "Address", "Age", "Archives", "Authorization documentation", "COVID-19", "COVID-19 pandemic", "Catalogs", "Cessation of life", "Clinical", "Clinical Data", "Code", "Cohort Studies", "Collaborations", "Collection", "Communities", "Coupled", "Data", "Data Analyses", "Data Science", "Data Set", "Development", "Disease", "Drug Targeting", "Ensure", "Environment", "Ethics", "European", "Fast Healthcare Interoperability Resources", "Finland", "Gender", "Genetic", "Genetic study", "Genome", "Genotype", "Health", "Healthcare", "Hospitalization", "Hospitals", "Human", "Individual", "Industrialization", "Infection", "Informatics", "Infrastructure", "Integration Host Factors", "International", "Intervention", "Investments", "Length of Stay", "Life Style", "Longitudinal cohort study", "Maps", "Measures", "Mediating", "Metadata", "Methods", "Modeling", "National Human Genome Research Institute", "Ontology", "Parkinson Disease", "Participant", "Patients", "Pharmacologic Substance", "Phenotype", "Policies", "Process", "Research", "Research Personnel", "Resources", "Risk Factors", "Role", "Scheme", "Secure", "Semantics", "Severity of illness", "Source", "Spain", "Standardization", "Stream", "Surveys", "Sweden", "Symptoms", "System", "Time", "Twin Studies", "Visualization", "base", "biobank", "burden of illness", "cohort", "comorbidity", "coronavirus disease", "data access", "data dictionary", "data integration", "data sharing", "demographics", "design", "disease heterogeneity", "distributed data", "genetic association", "genome wide association study", "genomic data", "human data", "improved", "novel", "personalized medicine", "phenome", "phenotypic data", "public health intervention", "sharing platform" ], "approved": true } }, { "type": "Grant", "id": "15744", "attributes": { "award_id": "1U19AI189183-01", "title": "Accelerator for the rapid development of countermeasures targeting drug resistant fungal pathogens", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32798, "first_name": "PING", "last_name": "CHEN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2030-06-30", "award_amount": 6977446, "principal_investigator": { "id": 8841, "first_name": "Arturo", "last_name": "Casadevall", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23143, "first_name": "David S", "last_name": "Perlin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1487, "ror": "https://ror.org/008zj0x80", "name": "Hackensack University Medical Center", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 2615, "ror": "", "name": "JOHNS HOPKINS UNIVERSITY", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Invasive fungal infections pose a significant medical challenge, particularly for individuals with compromised immune systems or other conditions due to HIV, cancer, organ transplantation, diabetes, chronic respiratory ailments, tuberculosis, COVID-19, and influenza. Prompt diagnosis and effective antifungal treatment are crucial for positive clinical outcomes. Current antifungal drugs are limited in number and efficacy, and their effectiveness has been compromised by the emergence of drug-resistant strains, notably Candida auris, Candida glabrata, and Aspergillus fumigatus. To combat this growing problem, there is an urgent need to develop new drugs capable of effectively treating invasive infections caused by drug-resistant fungal pathogens. Additionally, actionable point-of-care diagnostics for Candida bloodstream infections are essential for initiating timely and appropriate therapy, ultimately reducing overall mortality rates. While efforts from the biopharmaceutical industry have led to some expansion in the antifungal pipeline, more potent and targeted drugs are urgently required. In response to these pressing challenges, a Center of Excellence in Translational Research (CETR) focused on rapid drug and diagnostic development will be established. This Center harnesses expertise of leading academic and industry professionals, many of whom have a track record of successfully bringing FDA-approved products to market. The Projects selected encompass a wide range of new and established pharmacological drug targets, as well as a state-of-the-art diagnostic platform. Among the projects underway, collaborations with biopharmaceutical partners Prokaryotics and Scynexis are focused on the development of advanced small molecules targeting key enzymes involved in cell wall biogenesis. Additionally, efforts are underway to develop an antibody-based immunotherapy to combat drug-resistant infections. Finally, a Project dedicated to creating a novel point-of-care diagnostic capable of rapidly detecting Candida bloodstream infections in partnership with Cepheid Diagnostics on the GeneXpert platform, holds promise for revolutionizing the diagnosis and management of fungal infections. An integrated network of science cores staffed by experienced directors, facilitate efficient compound optimization and progression through clear ‘go, no-go’ metrics. While all programs prioritize high-threat drug-resistant Candida species, some drug candidates may also demonstrate efficacy against azole-resistant Aspergillus fumigatus. In summary, this CETR-based drug and diagnostic development accelerator represents a concerted effort to address the pressing need for novel treatments and diagnostics for invasive fungal infections. By leveraging the expertise of industry and world class translational academic partners, this initiative aims to rapidly advance innovative solutions to combat antifungal drug resistance and improve clinical outcomes for patients affected by these challenging fungal infections. The anticipated outcome of our successful efforts will be to create two IND-ready small molecule drug candidates, a lead optimized novel immunotherapy, and a 510(k) ready point-of-care diagnostic for bloodstream infections.", "keywords": [ "Academia", "Acceleration", "Address", "Advanced Development", "Affect", "Animal Model", "Antibodies", "Aspergillus fumigatus", "Azole resistance", "Biogenesis", "Biological Products", "Blood", "COVID-19", "Candida", "Candida auris", "Candida glabrata", "Cell Wall", "Chronic", "Clinical", "Collaborations", "Death Rate", "Dedications", "Detection", "Development", "Diabetes Mellitus", "Diagnosis", "Diagnostic", "Disease", "Drug Targeting", "Drug resistance", "Effectiveness", "Ensure", "Enzymes", "FDA approved", "Fungal Drug Resistance", "GPI Membrane Anchors", "Goals", "HIV", "Immune system", "Immunocompromised Host", "Immunotherapy", "Individual", "Industry", "Infection", "Influenza", "Investigational Drugs", "Knowledge", "Lead", "Life", "Malignant Neoplasms", "Marketing", "Medical", "Microbiology", "Mission", "Mycoses", "Organ Transplantation", "Outcome", "Patient-Focused Outcomes", "Pharmaceutical Chemistry", "Pharmaceutical Preparations", "Pharmacology", "Pharmacotherapy", "Process", "Productivity", "Public Health", "Rapid diagnostics", "Records", "Resistance", "Resistant candida", "Resources", "Respiration Disorders", "Science", "Standardization", "The science of Mycology", "Therapeutic", "Time", "Translational Research", "Transplantation", "Tuberculosis", "anti-fungal agents", "biopharmaceutical industry", "bloodstream infection", "combat", "diagnostic development", "diagnostic platform", "diagnostic tool", "diagnostic value", "drug candidate", "drug development", "experience", "formulation optimization", "glucan synthase", "improved", "in vivo", "in vivo Model", "innovation", "lead optimization", "mannoproteins", "mortality", "novel", "novel therapeutics", "pathogen", "pathogenic fungus", "pharmacologic", "point of care", "point-of-care diagnostics", "preclinical development", "prevent", "programs", "rapid detection", "resistant Aspergillus", "resistant strain", "respiratory", "response", "small molecule" ], "approved": true } }, { "type": "Grant", "id": "7357", "attributes": { "award_id": "3U19AI144297-02S1", "title": "GENOMIC APPROACHES TO UNDERSTAND DISEASE SUSCEPTIBILITY AND PATHOGENESIS OF SARS-COV-2", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 8282, "first_name": "Inka I", "last_name": "Sastalla", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-07-01", "end_date": "2022-06-30", "award_amount": 100000, "principal_investigator": { "id": 23147, "first_name": "RICHARD A", "last_name": "GIBBS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 566, "ror": "https://ror.org/02pttbw34", "name": "Baylor College of Medicine", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23148, "first_name": "Joseph Frank", "last_name": "Petrosino", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 566, "ror": "https://ror.org/02pttbw34", "name": "Baylor College of Medicine", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "OVERALL PROJECT SUMMARY The novel coronavirus, SARS-CoV-2, that was first detected in China in December 2019 has now spread globally. The Texas Medical Center in Houston, TX, the fourth largest city in the US, and among the top 10 in racial diversity, mounted an aggressive early response to the pandemic, primarily focused on acute care. Within Baylor College of Medicine, members of the TMC - Genomic Center for Infectious Disease (TMC-GCID) program (https://gcid.research.bcm.edu/overview) are leveraging existing infrastructure, together with an active and robust sample collection stream linked to both clinical and community testing, to characterize SARS-CoV-2 virulence and susceptibility across the region. This application requests supplemental funding to the TMC-GCID to help support SARS-CoV-2 community-wide surveillance, complete viral genome sequencing, nasopharyngeal microbiome profiling, and targeted host genetic analyses. The primary objective of this supplement will be achieved through the collaborative efforts of a multidisciplinary, integrated team of basic and physician scientists with a track-record of collaboration and who are already delivering on the primary goals of the TMC-GCID. The overall goals of our GCID supplement is to study the biology of SARS-CoV-2 infection, the host and microbial genetics associated with disease, and to address community needs, particularly in underserved communities, through the following aims: i) expand an operational Emergency Use Authorization- (EUA-) and IRB-compliant COVID-19 qPCR screening/surveillance program featuring online enrollment and consent as well as HIPAA-compliant return of results, ii) sequence and analyze full-length SARS-CoV-2 genomes from infected individuals collected from the TMC and surrounding area, iii) identify microbial co-colonization/co-infections that predict COVID-19 disease severity and/or outcome, iv) Characterize the host genetic variation with respect to viral titer, disease severity, and outcome in patients positive for COVID-19, including polymorphisms in human leukocyte antigen (HLA), angiotensin-converting enzyme 2 (ACE2), and natural killer cell immunoglobulin-like receptor (KIR) regions. This supplement will leverage the cutting edge, high-throughput sequencing strategies and technologies supplied by the TMC-GCID Sequencing Technology (ST) Core, in generating discoveries, data, tools, and reagents that will be analyzed and disseminated to the infectious disease community through the TMC-GCID Data Management Analysis and Resource Dissemination (DMARD) Core. The result will be a comprehensive genetic profiling of hosts and microbes in SARS-CoV-2 infection that will reveal pathogen genetic variants associated with individual host response phenotypes that will inform precision medicine-based therapeutics and diagnostics, not just for SARS-CoV-2, but for other pandemic threats that we have already observed to profoundly change the world around us.", "keywords": [ "2019-nCoV", "Address", "Age", "Area", "Authorization documentation", "Biology", "COVID-19", "China", "Cities", "Clinical", "Clonal Expansion", "Code", "Collaborations", "Collection", "Communicable Diseases", "Communities", "Consent", "Country", "DNA Sequence", "Data", "Detection", "Development", "Diagnostic", "Disease", "Disease susceptibility", "Emergency Situation", "Enrollment", "Ensure", "Funding", "Future", "Gender", "General Population", "Genetic Polymorphism", "Genetic Variation", "Genome", "Genomic Centers for Infectious Diseases", "Genomic approach", "Goals", "HLA Antigens", "Health Insurance Portability and Accountability Act", "High-Throughput Nucleotide Sequencing", "Immune response", "Immunoglobulins", "Individual", "Infection", "Infrastructure", "Institutional Review Boards", "Length", "Link", "Medical center", "Medicine", "Metadata", "Methods", "Microbe", "Microbial Genetics", "Natural Killer Cells", "Outcome", "Pathogenesis", "Patients", "Peptidyl-Dipeptidase A", "Phenotype", "Physicians", "Predisposition", "Protocols documentation", "Reagent", "Recombinant DNA", "Request for Applications", "Research", "Resources", "Reverse Transcriptase Polymerase Chain Reaction", "Role", "Sampling", "Scientist", "Sequence Analysis", "Severity of illness", "Shotguns", "Specimen", "Speed", "Stream", "Surveillance Program", "Symptoms", "Technology", "Testing", "Texas", "Therapeutic", "Time", "United States", "Variant", "Viral", "Viral Genome", "Virulence", "Virus", "acute care", "base", "co-infection", "college", "comorbidity", "cost", "data management", "data tools", "experience", "genetic analysis", "genetic profiling", "genetic variant", "genome sequencing", "infection rate", "innovation", "member", "metropolitan", "microbial", "microbiome", "multidisciplinary", "novel coronavirus", "novel diagnostics", "novel therapeutics", "pandemic disease", "pathogen", "precision medicine", "programs", "racial diversity", "receptor", "reconstruction", "repository", "response", "sample collection", "screening", "viral RNA", "virome", "virus genetics", "whole genome" ], "approved": true } } ], "meta": { "pagination": { "page": 1406, "pages": 1424, "count": 14236 } } }